Allosteric modulators of MEK1: drug design and discovery

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Chemical Biology and Drug Design

• Publication date

  2016-10-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1111/cbdd.12780PMID 27115708
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ras Conformational Ensembles, Allostery, and Signaling.

  2016cited by this paper
• ASD v3.0: unraveling allosteric regulation with structural mechanisms and biological networks

  2015cited by this paper
• ASBench: benchmarking sets for allosteric discovery

  2015cited by this paper
• The Mechanism of ATP-Dependent Allosteric Protection of Akt Kinase Phosphorylation.

  2015cited by this paper
• GTP Binding and Oncogenic Mutations May Attenuate Hypervariable Region (HVR)-Catalytic Domain Interactions in Small GTPase K-Ras4B, Exposing the Effector Binding Site*

  2015cited by this paper
• Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells.

  2015cited by this paper
• Recent computational advances in the identification of allosteric sites in proteins.

  2014cited by this paper
• Preclinical efficacy of MEK inhibition in Nras-mutant AML.

  2014cited by this paper
• The clinical development of MEK inhibitors

  2014cited by this paper
• Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases.

  2014cited by this paper
• Cancer therapeutics: Targeting the apoptotic pathway.

  2014cited by this paper
• Harnessing Allostery: A Novel Approach to Drug Discovery

  2014cited by this paper
• A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

  2014cited by this paper
• Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

  2013cited by this paper
• Allostery in disease and in drug discovery.

  2013cited by this paper
• Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

  2013cited by this paper
• A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours

  2013cited by this paper
• MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

  2013cited by this paper
• Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma

  2013cited by this paper
• Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.

  2013cited by this paper
• A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets

  2012cited by this paper
• Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

  2012cited by this paper
• Improved survival with MEK inhibition in BRAF-mutated melanoma.

  2012cited by this paper
• ERK1/2 MAP kinases: structure, function, and regulation.

  2012cited by this paper
• Fluorophore Labeled Kinase Detects Ligands That Bind within the MAPK Insert of p38α Kinase

  2012cited by this paper
• Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973).

  2012cited by this paper
• Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines

  2012cited by this paper
• Fused thiophene derivatives as MEK inhibitors.

  2012cited by this paper
• Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

  2012cited by this paper
• The different ways through which specificity works in orthosteric and allosteric drugs.

  2012cited by this paper
• Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactions.

  2012cited by this paper
• Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

  2012cited by this paper
• Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

  2012cited by this paper
• Engineering human MEK-1 for structural studies: A case study of combinatorial domain hunting.

  2012cited by this paper
• New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors.

  2012cited by this paper
• LIM kinases are attractive targets with many macromolecular partners and only a few small molecule regulators

  2012cited by this paper
• Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.

  2012cited by this paper
• GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

  2011cited by this paper
• Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer.

  2011cited by this paper
• Comprehensive analysis of kinase inhibitor selectivity

  2011cited by this paper
• Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent.

  2011cited by this paper
• Allo-network drugs: harnessing allostery in cellular networks.

  2011cited by this paper
• A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

  2011cited by this paper
• Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer

  2011cited by this paper
• Fully activated MEK1 exhibits compromised affinity for binding of allosteric inhibitors U0126 and PD0325901.

  2011cited by this paper
• Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo.

  2011cited by this paper
• Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

  2011cited by this paper
• The secret life of kinases: functions beyond catalysis

  2011cited by this paper
• Proteus in the World of Proteins: Conformational Changes in Protein Kinases

  2010cited by this paper
• MEK Inhibitor PD0325901 Significantly Reduces the Growth of Papillary Thyroid Carcinoma Cells In vitro and In vivo

  2010cited by this paper
• A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer

  2010cited by this paper
• Tanzanian malignant lymphomas: WHO classification, presentation, ploidy, proliferation and HIV/EBV association

  2010cited by this paper
• Structure-based design and synthesis of pyrrole derivatives as MEK inhibitors.

  2010cited by this paper
• BRAF mutation‐selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic‐potentiated synergism with the mTOR inhibitor temsirolimus

  2010cited by this paper
• The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

  2010cited by this paper
• Treatment of Hemodialyzed Patients with Sunitinib in Renal Cell Carcinoma

  2010cited by this paper
• Role of RAS in the regulation of PI 3-kinase.

  2010cited by this paper
• A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens

  2010cited by this paper
• The role of signaling pathways in the development and treatment of hepatocellular carcinoma

  2010cited by this paper
• Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.

  2010cited by this paper
• Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors.

  2009cited by this paper
• Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations.

  2009cited by this paper
• RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.

  2009cited by this paper
• Targeting cancer with small molecule kinase inhibitors

  2009cited by this paper
• The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker

  2009cited by this paper
• The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel

  2008cited by this paper
• Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.

  2008cited by this paper
• Allosteric regulation and catalysis emerge via a common route.

  2008cited by this paper
• The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.

  2008cited by this paper
• A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.

  2007cited by this paper
• The MEK/ERK cascade: from signaling specificity to diverse functions.

  2007cited by this paper
• Recent advances of MEK inhibitors and their clinical progress.

  2007cited by this paper
• Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration

  2007cited by this paper
• Clinical experience of MEK inhibitors in cancer therapy.

  2007cited by this paper
• Thermodynamics of nucleotide and non-ATP-competitive inhibitor binding to MEK1 by circular dichroism and isothermal titration calorimetry.

  2007cited by this paper
• AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models

  2007cited by this paper
• Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

  2007cited by this paper
• Mutation Analysis of BRAF, MEK1 and MEK2 in 15 Ovarian Cancer Cell Lines: Implications for Therapy

  2007cited by this paper
• Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases.

  2005cited by this paper
• Allosteric Mechanisms of Signal Transduction

  2005cited by this paper
• Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.

  2005cited by this paper
• Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

  2004cited by this paper
• The RAF proteins take centre stage

  2004cited by this paper
• Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.

  2004cited by this paper
• Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors

  2004cited by this paper
• Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

  2004cited by this paper
• Targeting the mitogen-activated protein kinase cascade to treat cancer

  2004cited by this paper
• Anti-Inflammatory Effects of Mitogen-Activated Protein Kinase Kinase Inhibitor U0126 in an Asthma Mouse Model1

  2004cited by this paper
• The biological profile of PD 0325901: A second generation analog of CI-1040 with improved pharmaceutical potential

  2004cited by this paper
• Anti-proliferative activity of the mTOR inhibitor AP23573 in combination with cytotoxic and targeted agents

  2004cited by this paper
• Preclinical development of ARRY-142886, a potent and selective MEK inhibitor

  2004cited by this paper
• Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.

  2003cited by this paper
• Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

  2002cited by this paper
• Protein kinases — the major drug targets of the twenty-first century?

  2002cited by this paper
• Cerulein-Induced Acute Pancreatitis in the Rat is Significantly Ameliorated by Treatment With MEK1/2 Inhibitors U0126 and PD98059

  2002cited by this paper
• The Protein Kinase Complement of the Human Genome

  2002cited by this paper
• Ras/Raf signalling and emerging pharmacotherapeutic targets

  2002cited by this paper
• Evolution of protein kinase signaling from yeast to man.

  2002cited by this paper
• Allosteric binding sites on cell-surface receptors: novel targets for drug discovery

  2002cited by this paper
• Mammalian MAP kinase signalling cascades

  2001cited by this paper

• Design and Synthesis of Novel MEK Inhibitors for the Treatment of Solid Tumors

  2025cites this paper
• In silico–guided synthesis of a new, highly soluble, and anti‐melanoma flavone glucoside: Skullcapflavone II‐6′‐O‐β‐glucoside

  2024cites this paper
• Islr regulates satellite cells asymmetric division through the SPARC/p‐ERK1/2 signaling pathway

  2024cites this paper
• Refrigerated amniotic membrane maintains its therapeutic qualities for 48 hours

  2024cites this paper
• Oleanolic Acid Complexation with Cyclodextrins Improves Its Cell Bio-Availability and Biological Activities for Cell Migration

  2023influential citation
• Exploring the potential of chromone scaffold compounds in cancer therapy: targeting key kinase pathways

  2023cites this paper
• Exploring the Natural Compounds in Flavonoids for Their Potential Inhibition of Cancer Therapeutic Target MEK1 Using Computational Methods

  2022cites this paper
• Oleanolic acid stimulation of cell migration involves a biphasic signaling mechanism

  2022cites this paper
• The protein kinase CK1: Inhibition, activation, and possible allosteric modulation

  2022cites this paper
• Allosterische Kinaseinhibitoren – Erwartungen und Chancen

  2020cites this paper
• A Redox-Sensitive Thiol in Wis1 Modulates the Fission Yeast Mitogen-Activated Protein Kinase Response to H2O2 and Is the Target of a Small Molecule

  2020cites this paper
• Function, Structure and Topology of Protein Kinases

  2020cites this paper
• Cytotoxic Effect of Vanicosides A and B from Reynoutria sachalinensis against Melanotic and Amelanotic Melanoma Cell Lines and in silico Evaluation for Inhibition of BRAFV600E and MEK1

  2020cites this paper
• A Redox-Sensitive Thiol in Wis1 Modulates the Fission Yeast Mitogen-Activated Protein Kinase Response to H₂O₂ and Is the Target of a Small Molecule

  2020cites this paper
• A redox-sensitive thiol in Wis1 modulates the fission yeast MAPK response to H2O2 and is the target of a small molecule

  2020cites this paper
• Activation of microglia synergistically enhances neurodegeneration caused by MPP+ in human SH‐SY5Y cells

  2019cites this paper
• New Promise and Opportunities for Allosteric Kinase Inhibitors.

  2019cites this paper
• Design, synthesis and biological evaluation of MEK PROTACs.

  2019cites this paper
• Allosteric Small-Molecule Serine/Threonine Kinase Inhibitors.

  2019cites this paper
• Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms

  2019cites this paper
• Macrocyclic MEK1/2 inhibitor with efficacy in a mouse model of cardiomyopathy caused by lamin A/C gene mutation.

  2017cites this paper
• Dependence of prevalence of contiguous pathways in proteins on structural complexity

  2017cites this paper
• The evolution of regulators of G protein signalling proteins as drug targets – 20 years in the making: IUPHAR Review 21

  2017cites this paper